Tenax Therapeutics (TENX) Cash & Equivalents (2010 - 2026)
Tenax Therapeutics recorded quarterly Cash & Equivalents of $118.8 million in Q1 2026, up 21.72% quarter-over-quarter from $97.6 million in Q4 2025, and up 6.56% year-over-year from $111.4 million in Q1 2025.
Tenax Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $118.8 million for Q1 2026.
- In Q1 2026, Cash & Equivalents rose 6.56% year-over-year to $118.8 million; the TTM figure through Mar 2026 stood at $118.8 million (up 6.56% YoY), while the FY2025 annual figure was $97.6 million, up 2.86% from the prior year.
- Cash & Equivalents came in at $118.8 million for Q1 2026 at Tenax Therapeutics, up from $97.6 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $118.8 million in Q1 2026 to a low of $2.1 million in Q4 2022.
- A 5-year average of $47.8 million and a median of $13.4 million in 2023 frame the typical range for Cash & Equivalents.
- Across the five-year window, Cash & Equivalents sank 61.96% in 2022 and jumped 1023.85% in 2025, its largest moves.
- Tenax Therapeutics' Cash & Equivalents stood at $2.1 million in 2022, then surged by 361.02% to $9.8 million in 2023, then soared by 868.66% to $94.9 million in 2024, then rose by 2.86% to $97.6 million in 2025, then grew by 21.72% to $118.8 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $118.8 million, $97.6 million, and $99.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Tenax Therapeutics | 542.72 Mn | 542.72 Mn | - | 118.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 118.76 Mn |
| Dec 31, 2025 | 97.57 Mn |
| Sep 30, 2025 | 99.37 Mn |
| Jun 30, 2025 | 105.46 Mn |
| Mar 31, 2025 | 111.45 Mn |
| Dec 31, 2024 | 94.85 Mn |
| Sep 30, 2024 | 98.31 Mn |
| Jun 30, 2024 | 9.38 Mn |
| Mar 31, 2024 | 12.55 Mn |
| Dec 31, 2023 | 9.79 Mn |
| Sep 30, 2023 | 11.14 Mn |
| Jun 30, 2023 | 13.39 Mn |
| Mar 31, 2023 | 14.41 Mn |
| Dec 31, 2022 | 2.12 Mn |
| Sep 30, 2022 | 3.81 Mn |
| Jun 30, 2022 | 7.23 Mn |
| Mar 31, 2022 | 2.90 Mn |
| Dec 31, 2021 | 5.58 Mn |
| Sep 30, 2021 | 8.35 Mn |
| Jun 30, 2021 | 1.67 Mn |
| Mar 31, 2021 | 3.54 Mn |
| Dec 31, 2020 | 6.25 Mn |
| Sep 30, 2020 | 8.24 Mn |
| Jun 30, 2020 | 4.09 Mn |
| Mar 31, 2020 | 4.36 Mn |
| Dec 31, 2019 | 4.91 Mn |
| Sep 30, 2019 | 6.65 Mn |
| Jun 30, 2019 | 8.41 Mn |
| Mar 31, 2019 | 10.32 Mn |
| Dec 31, 2018 | 12.37 Mn |
| Sep 30, 2018 | 3.35 Mn |
| Jun 30, 2018 | 3.90 Mn |
| Mar 31, 2018 | 2.99 Mn |
| Dec 31, 2017 | 1.60 Mn |
| Sep 30, 2017 | 1.76 Mn |
| Jun 30, 2017 | 2.23 Mn |
| Mar 31, 2017 | 7.03 Mn |
| Dec 31, 2016 | 10.00 Mn |
| Sep 30, 2016 | 722,152.00 |
| Jun 30, 2016 | 1.93 Mn |
| Mar 31, 2016 | 3.26 Mn |
| Dec 31, 2015 | 3.66 Mn |
| Sep 30, 2015 | 3.12 Mn |
| Jun 30, 2015 | 6.69 Mn |
| Apr 30, 2015 | 7.93 Mn |
| Apr 30, 2014 | 58.32 Mn |
| Apr 30, 2013 | 783,528.00 |
| Jan 31, 2013 | 828,811.00 |
| Oct 31, 2012 | 1.51 Mn |
| Jul 31, 2012 | 2.69 Mn |
| Apr 30, 2012 | 1.88 Mn |
| Jan 31, 2012 | 3.28 Mn |
| Oct 31, 2011 | 2.00 Mn |
| Jul 31, 2011 | 4.00 Mn |
| Apr 30, 2011 | 951,944.00 |
| Jan 31, 2011 | 522,340.00 |
| Oct 31, 2010 | 837,167.00 |
| Jul 31, 2010 | 2.73 Mn |